Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
30
WOK Quote, Financials, Valuation and Earnings
Last price:
$1.16
Seasonality move
:
3.87%
Day range:
$1.15 - $1.18
52-week range:
$1.05 - $10,800.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
3.41x
Volume:
8.6K
Avg. volume:
29.1K
1-year change:
-99.98%
Market cap:
$11.8K
Revenue:
$9.8M
EPS (TTM):
-$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WOK
WORK Medical Technology Group Ltd.
|
-- | -- | -- | -- | -- |
|
CTBO
Cantabio Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- |
|
GNLKQ
GeneLink, Inc.
|
-- | -- | -- | -- | -- |
|
LADX
LadRx Corp.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WOK
WORK Medical Technology Group Ltd.
|
$1.15 | -- | $11.8K | -- | $0.00 | 0% | 0.00x |
|
CTBO
Cantabio Pharmaceuticals, Inc.
|
$1.01 | -- | $22.7K | -- | $0.00 | 0% | -- |
|
GNLKQ
GeneLink, Inc.
|
$0.0000 | -- | $10.6K | -- | $0.00 | 0% | 0.01x |
|
LADX
LadRx Corp.
|
$0.0510 | -- | $25.3K | 0.84x | $0.00 | 0% | -- |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WOK
WORK Medical Technology Group Ltd.
|
58.17% | 4.342 | -- | 0.26x |
|
CTBO
Cantabio Pharmaceuticals, Inc.
|
-- | 0.000 | -- | -- |
|
GNLKQ
GeneLink, Inc.
|
-- | -83.814 | -- | -- |
|
LADX
LadRx Corp.
|
-- | 4.896 | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.237 | 12.91% | 11.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WOK
WORK Medical Technology Group Ltd.
|
-- | -- | -5.23% | -9.65% | -- | -- |
|
CTBO
Cantabio Pharmaceuticals, Inc.
|
-- | -- | -- | -- | -- | -- |
|
GNLKQ
GeneLink, Inc.
|
-- | -- | -- | -- | -- | -- |
|
LADX
LadRx Corp.
|
-- | -$719.8K | -- | -- | -- | -$552.8K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
WORK Medical Technology Group Ltd. vs. Competitors
-
Which has Higher Returns WOK or CTBO?
Cantabio Pharmaceuticals, Inc. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of --. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat Cantabio Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M CTBOCantabio Pharmaceuticals, Inc.-- -- -- -
What do Analysts Say About WOK or CTBO?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cantabio Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that WORK Medical Technology Group Ltd. has higher upside potential than Cantabio Pharmaceuticals, Inc., analysts believe WORK Medical Technology Group Ltd. is more attractive than Cantabio Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 CTBOCantabio Pharmaceuticals, Inc.0 0 0 -
Is WOK or CTBO More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cantabio Pharmaceuticals, Inc. has a beta of -0.167, suggesting its less volatile than the S&P 500 by 116.683%.
-
Which is a Better Dividend Stock WOK or CTBO?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cantabio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. Cantabio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or CTBO?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than Cantabio Pharmaceuticals, Inc. quarterly revenues of --. WORK Medical Technology Group Ltd.'s net income of -- is lower than Cantabio Pharmaceuticals, Inc.'s net income of --. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while Cantabio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.00x versus -- for Cantabio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.00x -- -- -- CTBOCantabio Pharmaceuticals, Inc.-- -- -- --
-
Which has Higher Returns WOK or GNLKQ?
GeneLink, Inc. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of --. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat GeneLink, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M GNLKQGeneLink, Inc.-- -- -- -
What do Analysts Say About WOK or GNLKQ?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand GeneLink, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that WORK Medical Technology Group Ltd. has higher upside potential than GeneLink, Inc., analysts believe WORK Medical Technology Group Ltd. is more attractive than GeneLink, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 GNLKQGeneLink, Inc.0 0 0 -
Is WOK or GNLKQ More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GeneLink, Inc. has a beta of -215.980, suggesting its less volatile than the S&P 500 by 21698.01%.
-
Which is a Better Dividend Stock WOK or GNLKQ?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeneLink, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. GeneLink, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or GNLKQ?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than GeneLink, Inc. quarterly revenues of --. WORK Medical Technology Group Ltd.'s net income of -- is lower than GeneLink, Inc.'s net income of --. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while GeneLink, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.00x versus 0.01x for GeneLink, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.00x -- -- -- GNLKQGeneLink, Inc.0.01x -- -- --
-
Which has Higher Returns WOK or LADX?
LadRx Corp. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of --. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat LadRx Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M LADXLadRx Corp.-- -$1.45 -- -
What do Analysts Say About WOK or LADX?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand LadRx Corp. has an analysts' consensus of -- which suggests that it could grow by 882252.94%. Given that LadRx Corp. has higher upside potential than WORK Medical Technology Group Ltd., analysts believe LadRx Corp. is more attractive than WORK Medical Technology Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 LADXLadRx Corp.0 0 0 -
Is WOK or LADX More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LadRx Corp. has a beta of 0.769, suggesting its less volatile than the S&P 500 by 23.083%.
-
Which is a Better Dividend Stock WOK or LADX?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LadRx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. LadRx Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or LADX?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than LadRx Corp. quarterly revenues of --. WORK Medical Technology Group Ltd.'s net income of -- is lower than LadRx Corp.'s net income of -$719.3K. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while LadRx Corp.'s PE ratio is 0.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.00x versus -- for LadRx Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.00x -- -- -- LADXLadRx Corp.-- 0.84x -- -$719.3K
-
Which has Higher Returns WOK or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to WORK Medical Technology Group Ltd.'s net margin of --. WORK Medical Technology Group Ltd.'s return on equity of -9.65% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital WOKWORK Medical Technology Group Ltd.-- -- $25.5M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About WOK or SVA?
WORK Medical Technology Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that WORK Medical Technology Group Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe WORK Medical Technology Group Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings WOKWORK Medical Technology Group Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is WOK or SVA More Risky?
WORK Medical Technology Group Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.313%.
-
Which is a Better Dividend Stock WOK or SVA?
WORK Medical Technology Group Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. WORK Medical Technology Group Ltd. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios WOK or SVA?
WORK Medical Technology Group Ltd. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. WORK Medical Technology Group Ltd.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, WORK Medical Technology Group Ltd.'s price-to-earnings ratio is -- while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for WORK Medical Technology Group Ltd. is 0.00x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WOKWORK Medical Technology Group Ltd.0.00x -- -- -- SVASinovac Biotech Ltd.1.50x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
